Back in January, Mannkind Corporation (MNKD) was denied yet again by the US FDA for its approval of the inhaled insulin spray Afrezza. The company subsequently laid off about 40% of its work force and shares were hammered after a conference call held by founder and CEO Alfred Mann - who has roughly a billion dollars of his own money invested in Mannkind and its flagship product Afrezza - failed to convince investors that he would front additional cash of his own to conduct the additional trial requested by the FDA as a prerequisite for approval.
Mr. Mann later clarified his statements and stressed that he - and the rest of the Mannkind staff - were 100% behind the continued development of Afrezza.
It has since been speculated that Mannkind will look to....
CLICK HERE FOR FULL ARTICLE